Investor Alert: Kaplan Fox Investigates Zogenix, Inc.
NEW YORK, April 15, 2019 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased shares of Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing rare disease therapies. Investors who purchased Zogenix securities between February 6, 2019 and April 8, 2019, inclusive (the "Class Period"), may be affected. A complaint has been filed in the United States District Court for the Northern District of California against the Company, its Chief Executive Officer, and its Chief Financial Officer.
On February 6, 2019, Zogenix issued a press release announcing that it had completed its rolling submission of a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for FINTEPLA® (ZX008, low-dose fenfluramine) for the treatment of seizures associated with Dravet syndrome.
On April 8, 2019, after the market closed, Zogenix issued a press release announcing the receipt of a Refusal to File letter from the FDA regarding its NDA for FINTEPLA. Among other things, the press release stated that "the FDA determined that the NDA, submitted on February 5, 2019, was not sufficiently complete to permit a substantive review." Further, the Company said that "[i]n the letter, the FDA cited two reasons for the RTF decision: first, certain non-clinical studies were not submitted to allow assessment of the chronic administration of fenfluramine; and, second, the application contained an incorrect version of a clinical dataset, which prevented the completion of the review process that is necessary to support the filing of the NDA."
On April 9, 2019, Zogeniz's shares fell $11.89 per share, about 23%, to close at $39.96 per share on heavy trading volume.
If you are a member of the proposed Class, you may move the court no later than June 11, 2019 to serve as a lead plaintiff for the purported class. You need not seek to become a lead plaintiff in order to share in any possible recovery. If you would like to discuss the complaint or our investigation, please contact us by emailing [email protected] or by calling 800-290-1952.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Kaplan Fox & Kilsheimer LLP, with offices in New York, San Francisco, Los Angeles, Chicago and New Jersey, has many years of experience in prosecuting investor class actions. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. If you have any questions about this Notice, the action, your rights, or your interests, please contact:
Jeffrey P. Campisi
KAPLAN FOX & KILSHEIMER LLP
850 Third Avenue, 14th Floor
New York, New York 10022
(800) 290-1952
(212) 687-1980
Fax: (212) 687-7714
E-mail: [email protected]
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
350 Sansome Street, Suite 400
San Francisco, California 94104
(415) 772-4700
Fax: (415) 772-4707
E-mail: [email protected]
SOURCE Kaplan Fox & Kilsheimer LLP
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article